These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33011650)

  • 21. A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase.
    Sharling L; Liu X; Gollapalli DR; Maurya SK; Hedstrom L; Striepen B
    PLoS Negl Trop Dis; 2010 Aug; 4(8):e794. PubMed ID: 20706578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
    Zhang Z; Ojo KK; Johnson SM; Larson ET; He P; Geiger JA; Castellanos-Gonzalez A; White AC; Parsons M; Merritt EA; Maly DJ; Verlinde CL; Van Voorhis WC; Fan E
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5264-7. PubMed ID: 22795629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of P23 of Cryptosporidium parvum in Toxoplasma gondii and evaluation of its protective effects.
    Shirafuji H; Xuan X; Kimata I; Takashima Y; Fukumoto S; Otsuka H; Nagasawa H; Suzuki H
    J Parasitol; 2005 Apr; 91(2):476-9. PubMed ID: 15986633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetases.
    Guo F; Zhang H; Fritzler JM; Rider SD; Xiang L; McNair NN; Mead JR; Zhu G
    J Infect Dis; 2014 Apr; 209(8):1279-87. PubMed ID: 24273180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mass Spectrometry Imaging of In Vitro
    Anschütz NH; Gerbig S; Ghezellou P; Silva LMR; Vélez JD; Hermosilla CR; Taubert A; Spengler B
    Biomolecules; 2023 Jul; 13(8):. PubMed ID: 37627264
    [No Abstract]   [Full Text] [Related]  

  • 26. Identification of fungal natural products with potent inhibition in
    Jiang T; Godinez-Macias KP; Collins JE; Lee JW; Wendt KL; Carolino K; Chakrabarti D; Cichewicz RH; Winzeler EA
    Microbiol Spectr; 2024 Apr; 12(4):e0414223. PubMed ID: 38421191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current progress in the fatty acid metabolism in Cryptosporidium parvum.
    Zhu G
    J Eukaryot Microbiol; 2004; 51(4):381-8. PubMed ID: 15352319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The unusual architecture and predicted function of the mitochondrion organelle in Cryptosporidium parvum and hominis species: the strong paradigm of the structure-function relationship.
    Putignani L
    Parassitologia; 2005 Jun; 47(2):217-25. PubMed ID: 16252476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Production and Purification of Functional Cryptosporidium Glycoproteins by Heterologous Expression in Toxoplasma gondii.
    Driskell I; O'Connor RM
    Methods Mol Biol; 2020; 2052():87-102. PubMed ID: 31452158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elongation factor-1α is a novel protein associated with host cell invasion and a potential protective antigen of Cryptosporidium parvum.
    Matsubayashi M; Teramoto-Kimata I; Uni S; Lillehoj HS; Matsuda H; Furuya M; Tani H; Sasai K
    J Biol Chem; 2013 Nov; 288(47):34111-34120. PubMed ID: 24085304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of New Inhibitors of Toxoplasma gondii via the Pathogen Box.
    Spalenka J; Escotte-Binet S; Bakiri A; Hubert J; Renault JH; Velard F; Duchateau S; Aubert D; Huguenin A; Villena I
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133550
    [No Abstract]   [Full Text] [Related]  

  • 32. Cryptosporidium and Toxoplasma Parasites Are Inhibited by a Benzoxaborole Targeting Leucyl-tRNA Synthetase.
    Palencia A; Liu RJ; Lukarska M; Gut J; Bougdour A; Touquet B; Wang ED; Li X; Alley MR; Freund YR; Rosenthal PJ; Hakimi MA; Cusack S
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5817-27. PubMed ID: 27431220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phthalazinone inhibitors of inosine-5'-monophosphate dehydrogenase from Cryptosporidium parvum.
    Johnson CR; Gorla SK; Kavitha M; Zhang M; Liu X; Striepen B; Mead JR; Cuny GD; Hedstrom L
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1004-7. PubMed ID: 23324406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of freeze-thaw cycles for nucleic acid extraction and molecular detection of Cryptosporidium parvum and Toxoplasma gondii oocysts in environmental matrices.
    Manore AJW; Harper SL; Aguilar B; Weese JS; Shapiro K
    J Microbiol Methods; 2019 Jan; 156():1-4. PubMed ID: 30468750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of Cpgp40/15 in Toxoplasma gondii: a surrogate system for the study of Cryptosporidium glycoprotein antigens.
    O'Connor RM; Kim K; Khan F; Ward HD
    Infect Immun; 2003 Oct; 71(10):6027-34. PubMed ID: 14500524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defining Stage-Specific Activity of Potent New Inhibitors of Cryptosporidium parvum Growth
    Funkhouser-Jones LJ; Ravindran S; Sibley LD
    mBio; 2020 Mar; 11(2):. PubMed ID: 32127445
    [No Abstract]   [Full Text] [Related]  

  • 37. Lower micromolar activity of the antifungal imidazoles on the bacterial-type bifunctional aldehyde/alcohol dehydrogenase (AdhE) in Cryptosporidium parvum and in vitro efficacy against the zoonotic parasite.
    Chen H; Wang D; Wang C; Jiang P; Liu M; Yin J; Yu Y
    Int J Parasitol Drugs Drug Resist; 2024 Aug; 25():100551. PubMed ID: 38875756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth.
    Bessoff K; Sateriale A; Lee KK; Huston CD
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1804-14. PubMed ID: 23380723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent and selective inhibitors of CDPK1 from
    Zhang Z; Ojo KK; Vidadala R; Huang W; Geiger JA; Scheele S; Choi R; Reid MC; Keyloun KR; Rivas K; Siddaramaiah LK; Comess KM; Robinson KP; Merta PJ; Kifle L; Hol WG; Parsons M; Merritt EA; Maly DJ; Verlinde CL; Van Voorhis WC; Fan E
    ACS Med Chem Lett; 2014 Jan; 5(1):40-44. PubMed ID: 24494061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target.
    Yang B; Yan Y; Wang D; Zhang Y; Yin J; Zhu G
    PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011217. PubMed ID: 36972284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.